Report Highlights

U.S. Metagenomic Sequencing Market Overview

The U.S. metagenomic sequencing market reached USD 680 million in 2024 and is projected to reach USD 1.9 billion by 2032 at a 13.7% CAGR, one of the fastest growth rates in the U.S. clinical diagnostics market, driven by the maturation of next-generation sequencing platform performance and cost to clinical applicability thresholds, the growing pipeline of FDA regulatory pathway submissions for mNGS clinical products, and the demonstrated clinical utility of mNGS in infectious disease diagnosis, microbiome characterisation, and environmental pathogen surveillance applications that conventional molecular diagnostic methods cannot address with equivalent breadth and sensitivity. Metagenomic sequencing analyses all genetic material in a clinical or environmental sample simultaneously — without requiring target-specific primers, probes, or culture conditions — enabling unbiased detection of any pathogen or microbial community member present in the sample at concentrations above the sequencing depth's analytical sensitivity threshold.

The U.S. mNGS market spans three commercially distinct applications with different revenue dynamics. Clinical infectious disease mNGS — detecting pathogens in blood, cerebrospinal fluid, respiratory specimens, and tissue biopsies from symptomatic patients — is the highest-value-per-test segment with clinical diagnostic pricing of USD 500–2,500 per test when clinical utility evidence supports physician ordering and payer coverage. Microbiome research and profiling — characterising the microbial composition of gut, skin, oral, and other body-site microbiomes for research, wellness, and therapeutic response monitoring applications — represents the highest-volume segment by sample count but with lower per-test revenue for research-grade versus clinical-grade analysis. Environmental metagenomics — wastewater surveillance for pathogen prevalence monitoring, food safety pathogen detection, and biosecurity applications — is a rapidly growing government and regulatory-funded segment that expanded significantly during COVID-19 wastewater surveillance programmes and is being sustained through CDC BioSense infrastructure and state public health laboratory investment.

Growth Drivers for U.S. Metagenomic Sequencing Market

Three demand drivers sustain the U.S. metagenomic sequencing market's growth through 2032. The antimicrobial stewardship imperative — where U.S. hospitals and health systems are under regulatory and accreditation pressure to reduce empirical broad-spectrum antibiotic use and transition toward pathogen-directed narrow-spectrum therapy — creates institutional demand for rapid comprehensive pathogen identification that mNGS uniquely provides when conventional culture methods are too slow or insufficiently sensitive to guide timely therapeutic decisions. CDC's National Action Plan for Combating Antibiotic-Resistant Bacteria explicitly identifies rapid diagnostic methods that enable earlier pathogen identification and antimicrobial resistance characterisation as priority investments, and CMS's Hospital Acquired Conditions reduction programme creates financial incentives for hospitals to adopt diagnostic tools that reduce healthcare-associated infections through more targeted antimicrobial management. The immunocompromised patient population's growth — driven by the expanding use of immunosuppressive biological therapies, the increasing prevalence of solid organ transplantation, and the ageing population's higher immunosuppressive medication burden — is creating growing clinical demand for mNGS in the high-risk patient populations where its clinical utility advantage over conventional diagnostics is greatest.

The oncology microbiome opportunity — where the tumour microenvironment's microbial composition is being investigated as a modulator of immunotherapy response, chemotherapy efficacy, and surgical outcome — is creating a research mNGS application of extraordinary commercial potential for the sequencing platforms and bioinformatics companies serving the cancer research market. Multiple published studies have demonstrated correlations between gut and tumour microbiome composition and PD-1/PD-L1 immunotherapy response in melanoma, lung cancer, and renal cell carcinoma, driving pharmaceutical company investment in microbiome profiling of clinical trial patient populations that is expanding mNGS market volume in the oncology research segment at above-market rates. The wastewater surveillance programme's institutionalisation through CDC infrastructure spending — following the demonstrated public health value of SARS-CoV-2 wastewater surveillance during the COVID-19 pandemic — is sustaining environmental metagenomics market growth through ongoing state and local health department funding for wastewater epidemiology programmes that track influenza, RSV, mpox, and emerging pathogen prevalence trends in the community.

Regulatory and Reimbursement Environment

The U.S. metagenomic sequencing regulatory landscape is at a critical transition point between the LDT-operated model that has characterised clinical mNGS since its emergence and the FDA-cleared clinical diagnostic model that is beginning to establish regulatory precedents through breakthrough device designations and de novo clearance submissions. Clinical mNGS tests currently offered by CLIA-certified clinical laboratories — including Karius's ctmNGS blood test and IDbyDNA's Explify respiratory pathogen panel — operate as laboratory-developed tests under CLIA oversight without current FDA IVD clearance, a regulatory status that the FDA's 2023 LDT Proposed Rule would change by imposing FDA regulatory requirements on LDT-based mNGS tests. FDA's Breakthrough Device Designation for multiple clinical mNGS applications — including IDbyDNA's pneumonia diagnostics and Karius's bloodstream infection detection — indicates that FDA is actively supporting the regulatory pathway development for clinical mNGS rather than requiring novel device classification frameworks that do not yet exist.

Reimbursement for clinical mNGS is the most commercially limiting factor in the clinical diagnostic segment's growth. Medicare coverage for clinical mNGS is currently established through Miscellaneous CPT codes and Genomic Sequence Analysis (GSA) codes that provide reimbursement of USD 500–1,200 per test for specific clinical mNGS applications in defined patient populations — below the per-test cost of clinical-grade mNGS at current sequencing economics for most clinical applications, creating a reimbursement coverage gap that limits clinical mNGS adoption to academic medical centres with institutional cross-subsidisation tolerance and cash-pay patient segments with financial access to non-covered testing. MolDX's LCD L38568 for next-generation sequencing-based infectious disease diagnostics provides the most commercially useful Medicare coverage framework currently available, covering clinical mNGS for specific indications including immunocompromised patient infectious disease evaluation at the academic medical centre facilities enrolled in the MolDX programme.

Market Opportunities in U.S. Metagenomic Sequencing Market

The cerebrospinal fluid metagenomics opportunity represents the single highest-clinical-impact mNGS application in acute care — where the differential diagnosis of infectious versus autoimmune encephalitis, meningitis, and brain abscess requires rapid, comprehensive pathogen identification from CSF that conventional culture and PCR panel methods address incompletely and too slowly for time-sensitive treatment decisions. UCSF's HHMI-funded mNGS programme demonstrated that CSF mNGS identified causative pathogens in 13% of encephalitis cases where conventional workup was negative — pathogens whose identification directly changed treatment and prevented adverse outcomes. The clinical utility data for CSF mNGS is the most compelling of any mNGS application for supporting FDA clearance submissions and commercial payer coverage requests, making it the highest-priority clinical indication for mNGS clinical diagnostic companies seeking to establish the reimbursement infrastructure that drives mainstream clinical adoption.

The pharmacomicrobiomics opportunity — studying how the gut microbiome influences drug metabolism, therapeutic response, and adverse effect profiles — is creating demand for clinical mNGS in pharmaceutical clinical trials and eventually in clinical practice as actionable pharmacomicrobiome relationships are validated. Specific microbiome compositions have been associated with differential response to cyclophosphamide, irinotecan, gemcitabine, and immune checkpoint inhibitors — creating drug development demand for microbiome profiling of clinical trial cohorts and a long-term clinical practice demand for microbiome-guided drug prescribing decisions that mNGS is uniquely positioned to enable through comprehensive microbial community characterisation from stool specimens.

Market at a Glance

Leading Market Participants

• Illumina
• Karius
• IDbyDNA (Illumina)
• CosmosID
• Whole Biome
• Second Genome
• Diversigen (Bioventus)
• Clinical Microbiomics
• Pacific Biosciences
• Oxford Nanopore Technologies

Competitive Outlook for U.S. Metagenomic Sequencing Market

The U.S. metagenomic sequencing market will reach USD 1.9 billion by 2032, with the competitive dynamics fundamentally restructured by two anticipated regulatory events — the finalisation of the FDA LDT Proposed Rule and the first FDA de novo clearances for clinical mNGS infectious disease diagnostic products. Companies that achieve FDA clearance status before LDT rule finalisation will hold durable competitive advantages in hospital purchasing decisions, commercial payer coverage negotiations, and academic medical centre adoption that LDT-only operators will struggle to overcome once the regulatory environment requires FDA compliance from all clinical mNGS operators. The sequencing platform evolution — particularly Oxford Nanopore's long-read real-time sequencing capability that enables same-day mNGS results versus the 24–48 hour turnaround of short-read Illumina sequencing — will define the competitive technology landscape by 2028, as clinical applications where turnaround time is the primary clinical value driver migrate toward long-read platforms whose per-base sequencing cost continues to decline toward clinical economic viability.

The most commercially significant consolidation in the U.S. mNGS market will be the acquisition of clinical mNGS diagnostic companies by major IVD manufacturers — Roche Diagnostics, Thermo Fisher, and Illumina's own diagnostics division — who are building mNGS clinical diagnostic capability to complement their conventional molecular diagnostics portfolios. These acquisitions will accelerate clinical mNGS commercial deployment by providing hospital laboratory relationships, FDA regulatory infrastructure, and commercial insurance contracting capability that stand-alone mNGS companies typically lack. The acquisition wave is anticipated between 2025 and 2028 as FDA clearance precedents are established and the clinical mNGS market's commercial trajectory becomes sufficiently visible to justify the M&A premium that early-stage mNGS diagnostic companies will command from IVD strategic acquirers.